兔抗KRCC1多克隆抗体

Background:

The 21 kDa guanine-nucleotide binding proteins (K-Ras, H-Ras, and N-Ras) cycle between active (GTP-bound) and inactive (GDP-bound) forms. Receptor tyrosine kinases and G protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway. GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, research studies have shown that in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway. The most common oncogenic Ras mutation found in tumors is Gly12 to Asp12 (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein.

Applications:

WB

Name of antibody:

KRAS

Immunogen:

Fusion protein of human KRAS

Full name:

v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog

Synonyms：

KRAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KI-RAS; KRAS1; KRAS2; NS3; RASK2

SwissProt:

P01116

WB Predicted band size:

21 kDa

WB Positive control:

Brain tissue

WB Recommended dilution:

500-2000